{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T04:12:37Z","timestamp":1749701557603,"version":"3.41.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["U18FD007054"],"award-info":[{"award-number":["U18FD007054"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n            <jats:title>Graphical Abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1007\/s11095-025-03839-x","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T19:41:01Z","timestamp":1741376461000},"page":"737-746","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Considering Opportunities and Challenges When Implementing the Model Master File Framework \u2013 a Meeting Report"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1993-8528","authenticated-orcid":false,"given":"Eleftheria","family":"Tsakalozou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanyan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Skoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Nicholas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sivacharan","family":"Kollipara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stella","family":"Grosser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhagwant","family":"Rege","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Partha","family":"Roy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"issue":"5","key":"3839_CR1","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/psp4.12600","volume":"10","author":"E Tsakalozou","year":"2021","unstructured":"Tsakalozou E, Babiskin A, Zhao L. Physiologically-based pharmacokinetic modeling to support bioequivalence and approval of generic products: A case for diclofenac sodium topical gel, 1. CPT Pharmacom Syst Pharmacol. 2021;10(5):399\u2013411.","journal-title":"CPT Pharmacom Syst Pharmacol"},{"issue":"Suppl 1","key":"3839_CR2","first-page":"S160","volume":"60","author":"X Zhang","year":"2020","unstructured":"Zhang X, Yang Y, Grimstein M, Fan J, Grillo JA, Huang SM, et al. Application of PBPK Modeling and Simulation for Regulatory Decision Making and Its Impact on US Prescribing Information: An Update on the 2018\u20132019 Submissions to the US FDA\u2019s Office of Clinical Pharmacology. J Clin Pharmacol. 2020;60(Suppl 1):S160\u201378.","journal-title":"J Clin Pharmacol"},{"key":"3839_CR3","unstructured":"FDA Guidance Document. Physiologically based pharmacokinetic analyses \u2014 Format and content guidance for industry, September 2018, Issued by: Center for drug evaluation and research Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/physiologically-based-pharmacokinetic-analyses-format-and-content-guidance-industry#:~:text=To%20enable%20efficient%20and%20consistent,%3B%20and%20(F)%20Appendices. Accessed 18 Feb 2025."},{"key":"3839_CR4","unstructured":"FDA guidance document: the use of physiologically based pharmacokinetic analyses \u2014 biopharmaceutics applications for oral drug product development, manufacturing changes, and controls, Draft guidance for industry, September 2020, Issued by: Center for Drug Evaluation and Research. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/use-physiologically-based-pharmacokinetic-analyses-biopharmaceutics-applications-oral-drug-product. Accessed 18 Feb 2025."},{"issue":"3","key":"3839_CR5","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/cpt.2643","volume":"112","author":"X Chu","year":"2022","unstructured":"Chu X, Prasad B, Neuhoff S, Yoshida K, Leeder JS, Mukherjee D, et al. Clinical implications of altered drug transporter abundance\/function and PBPK modeling in specific populations: an ITC perspective. Clin Pharmacol Ther. 2022;112(3):501\u201326.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"3839_CR6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/cpt.37","volume":"97","author":"HM Jones","year":"2015","unstructured":"Jones HM, Chen Y, Gibson C, Heimbach T, Parrott N, Peters SA, et al. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. Clin Pharmacol Ther. 2015;97(3):247\u201362.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"3839_CR7","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/cpt.3289","volume":"116","author":"K Rowland Yeo","year":"2024","unstructured":"Rowland Yeo K, Gil Berglund E, Chen Y. Dose optimization informed by PBPK modeling: state-of-the art and future. Clin Pharmacol Ther. 2024;116(3):563\u201376.","journal-title":"Clin Pharmacol Ther"},{"key":"3839_CR8","doi-asserted-by":"publisher","first-page":"107541","DOI":"10.1016\/j.pharmthera.2020.107541","volume":"211","author":"LFM Verscheijden","year":"2020","unstructured":"Verscheijden LFM, Koenderink JB, Johnson TN, de Wildt SN, Russel FGM. Physiologically-based pharmacokinetic models for children: starting to reach maturation? Pharmacol Ther. 2020;211:107541.","journal-title":"Pharmacol Ther"},{"issue":"8","key":"3839_CR9","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s11095-022-03274-2","volume":"39","author":"W Lin","year":"2022","unstructured":"Lin W, Chen Y, Unadkat JD, Zhang X, Wu D, Heimbach T. Applications, challenges, and outlook for PBPK modeling and simulation: a regulatory, industrial and academic perspective. Pharm Res. 2022;39(8):1701\u201331.","journal-title":"Pharm Res"},{"issue":"8","key":"3839_CR10","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1007\/s11095-022-03280-4","volume":"39","author":"O Anand","year":"2022","unstructured":"Anand O, Pepin XJH, Kolhatkar V, Seo P. The use of physiologically based pharmacokinetic analyses-in biopharmaceutics applications -regulatory and industry perspectives. Pharm Res. 2022;39(8):1681\u2013700.","journal-title":"Pharm Res"},{"issue":"2","key":"3839_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1208\/s12248-021-00564-2","volume":"23","author":"F Wu","year":"2021","unstructured":"Wu F, Shah H, Li M, Duan P, Zhao P, Suarez S, et al. Biopharmaceutics applications of physiologically based pharmacokinetic absorption modeling and simulation in regulatory submissions to the U.S. food and drug administration for new drugs. AAPS J. 2021;23(2):31.","journal-title":"AAPS J."},{"issue":"7","key":"3839_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1208\/s12249-024-02904-9","volume":"25","author":"AK Bhattiprolu","year":"2024","unstructured":"Bhattiprolu AK, Kollipara S, Boddu R, Arumugam A, Khan SM, Ahmed T. A semi-mechanistic physiologically based biopharmaceutics model to describe complex and saturable absorption of metformin: justification of dissolution specifications for extended release formulation. AAPS PharmSciTech. 2024;25(7):193.","journal-title":"AAPS PharmSciTech"},{"issue":"5","key":"3839_CR13","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1021\/acs.molpharmaceut.4c00202","volume":"21","author":"C Mackie","year":"2024","unstructured":"Mackie C, Arora S, Seo P, Moody R, Rege B, Pepin X, et al. Physiologically Based Biopharmaceutics Modeling (PBBM): best practices for drug product quality, regulatory and industry perspectives: 2023 workshop summary report. Mol Pharm. 2024;21(5):2065\u201380.","journal-title":"Mol Pharm"},{"issue":"2","key":"3839_CR14","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.xphs.2020.10.059","volume":"110","author":"A Mitra","year":"2021","unstructured":"Mitra A, Suarez-Sharp S, Pepin XJH, Flanagan T, Zhao Y, Kotzagiorgis E, et al. Applications of Physiologically Based Biopharmaceutics Modeling (PBBM) to support drug product quality: a workshop summary report. J Pharm Sci. 2021;110(2):594\u2013609.","journal-title":"J Pharm Sci"},{"issue":"2","key":"3839_CR15","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.xphs.2023.11.030","volume":"113","author":"S Kollipara","year":"2024","unstructured":"Kollipara S, Martins FS, Sanghavi M, Santos GML, Saini A, Ahmed T. Role of Physiologically Based Biopharmaceutics Modeling (PBBM) in fed bioequivalence study waivers: regulatory outlook, case studies and future perspectives. J Pharm Sci. 2024;113(2):345\u201358.","journal-title":"J Pharm Sci"},{"issue":"12","key":"3839_CR16","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1016\/j.xphs.2021.09.017","volume":"110","author":"T Heimbach","year":"2021","unstructured":"Heimbach T, Kesisoglou F, Novakovic J, Tistaert C, Mueller-Zsigmondy M, Kollipara S, et al. Establishing the bioequivalence safe space for immediate-release oral dosage forms using Physiologically Based Biopharmaceutics Modeling (PBBM): case studies. J Pharm Sci. 2021;110(12):3896\u2013906.","journal-title":"J Pharm Sci"},{"issue":"5","key":"3839_CR17","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/psp4.12931","volume":"12","author":"Y Gong","year":"2023","unstructured":"Gong Y, Zhang P, Yoon M, Zhu H, Kohojkar A, Hooker AC, et al. Establishing the suitability of model-integrated evidence to demonstrate bioequivalence for long-acting injectable and implantable drug products: Summary of workshop. CPT Pharmacom Syst Pharmacol. 2023;12(5):624\u201330.","journal-title":"CPT Pharmacom Syst Pharmacol"},{"issue":"3","key":"3839_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1208\/s12248-024-00916-8","volume":"26","author":"A Pal","year":"2024","unstructured":"Pal A, Wu F, Walenga R, Tsakalozou E, Alam K, Gong Y, et al. Leveraging modeling and simulation to enhance the efficiency of bioequivalence approaches for generic drugs: highlights from the 2023 generic drug science and research initiatives public workshop. AAPS J. 2024;26(3):45.","journal-title":"AAPS J"},{"issue":"1","key":"3839_CR19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1208\/s12248-023-00879-2","volume":"26","author":"RL Walenga","year":"2024","unstructured":"Walenga RL, Babiskin AH, Bhoopathy S, Clarke JF, De Backer J, Ducharme M, et al. Use of the same model or modeling strategy across multiple submissions: focus on complex drug products. AAPS J. 2024;26(1):12.","journal-title":"AAPS J"},{"issue":"5","key":"3839_CR20","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/psp4.12930","volume":"12","author":"M Yoon","year":"2023","unstructured":"Yoon M, Babiskin A, Hu M, Wu F, Raney SG, Fang L, et al. Increasing impact of quantitative methods and modeling in establishment of bioequivalence and characterization of drug delivery. CPT Pharmacom Syst Pharmacol. 2023;12(5):552\u20135.","journal-title":"CPT Pharmacom Syst Pharmacol"},{"issue":"4","key":"3839_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1208\/s12248-023-00826-1","volume":"25","author":"G Pawar","year":"2023","unstructured":"Pawar G, Wu F, Zhao L, Fang L, Burckart GJ, Feng K, et al. Integration of biorelevant pediatric dissolution methodology into PBPK modeling to predict in vivo performance and bioequivalence of generic drugs in pediatric populations: a carbamazepine case study. AAPS J. 2023;25(4):67.","journal-title":"AAPS J"},{"issue":"1","key":"3839_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1208\/s12248-024-00886-x","volume":"26","author":"F Wu","year":"2024","unstructured":"Wu F, Mousa Y, Jereb R, Batchelor H, Chakraborty S, Heimbach T, et al. Using mechanistic modeling approaches to support bioequivalence assessments for oral products. AAPS J. 2024;26(1):19.","journal-title":"AAPS J"},{"key":"3839_CR23","unstructured":"FDA-CRCG hosted free virtual public workshop: regulatory utility of mechanistic modeling to support alternative bioequivalence approaches. September 30 \u2013 October 1, 2021. Available from: https:\/\/www.complexgenerics.org\/education-training\/regulatory-utility-of-mechanistic-modeling-to-support-alternative-bioequivalence-approaches\/. Accessed 18 Feb 2025."},{"key":"3839_CR24","unstructured":"FDA-CRCG hosted free virtual public workshop: best practices for utilizing modeling approaches to support generic product development. October 27\u201328, 2022. Available from: https:\/\/www.complexgenerics.org\/education-training\/best-practices-for-utilizing-modeling-approaches-to-support-generic-product-development\/. Accessed 18 Feb 2025."},{"issue":"2","key":"3839_CR25","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1208\/s12248-024-00897-8","volume":"26","author":"L Fang","year":"2024","unstructured":"Fang L, Gong Y, Hooker AC, Lukacova V, Rostami-Hodjegan A, Sale M, et al. The role of model master files for sharing, acceptance, and communication with FDA. AAPS J. 2024;26(2):28.","journal-title":"AAPS J"},{"key":"3839_CR26","unstructured":"FDA-CRCG hosted free virtual public workshop: considerations and potential regulatory applications for a model master file. May 2\u20133, 2024. Available from: https:\/\/www.complexgenerics.org\/education-training\/considerations-and-potential-regulatory-applications-for-a-model-master-file\/. Accessed 18 Feb 2025."},{"key":"3839_CR27","unstructured":"Model-informed drug development paired meeting program offered by the US FDA. Available from: https:\/\/www.fda.gov\/drugs\/development-resources\/model-informed-drug-development-paired-meeting-program. Accessed 18 Feb 2025."},{"key":"3839_CR28","unstructured":"Model-integrated evidence (MIE) industry meeting pilot between FDA and generic drug applicants [Available from: https:\/\/www.fda.gov\/drugs\/abbreviated-new-drug-application-anda\/model-integrated-evidence-mie-industry-meeting-pilot-between-fda-and-generic-drug-applicants. Accessed 18 Feb 2025."},{"key":"3839_CR29","unstructured":"Drug master files. Available from: https:\/\/www.fda.gov\/drugs\/forms-submission-requirements\/drug-master-files-dmfs. Accessed 18 Feb 2025."},{"key":"3839_CR30","unstructured":"Drug master files, draft guidance for industry, U.S. department of health and human services, food and drug administration, center for drug evaluation and research (CDER), center for biologics evaluation and research (CBER October 2019, Pharmaceutical Quality\/CMC. Available from: https:\/\/www.fda.gov\/media\/131861\/download. Accessed 18 Feb 2025."},{"key":"3839_CR31","unstructured":"List of drug master files (DMFs). Available from: https:\/\/www.fda.gov\/drugs\/drug-master-files-dmfs\/list-drug-master-files-dmfs. Accessed 18 Feb 2025."},{"issue":"3","key":"3839_CR32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1208\/s12248-023-00792-8","volume":"25","author":"V Purohit","year":"2023","unstructured":"Purohit V, Huh Y, Wojciechowski J, Plotka A, Salts S, Antinew J, et al. Leveraging prior healthy participant pharmacokinetic data to evaluate the impact of renal and hepatic impairment on ritlecitinib pharmacokinetics. AAPS J. 2023;25(3):32.","journal-title":"AAPS J"},{"issue":"1","key":"3839_CR33","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/cts.12492","volume":"11","author":"DJ Conrado","year":"2018","unstructured":"Conrado DJ, Nicholas T, Tsai K, Macha S, Sinha V, Stone J, et al. Dopamine transporter neuroimaging as an enrichment biomarker in early Parkinson\u2019s disease clinical trials: a disease progression modeling analysis. Clin Transl Sci. 2018;11(1):63\u201370.","journal-title":"Clin Transl Sci"},{"issue":"4","key":"3839_CR34","doi-asserted-by":"publisher","first-page":"825","DOI":"10.3233\/JPD-199003","volume":"9","author":"D Stephenson","year":"2019","unstructured":"Stephenson D, Hill D, Cedarbaum JM, Tome M, Vamvakas S, Romero K, et al. The qualification of an enrichment biomarker for clinical trials targeting early stages of Parkinson\u2019s disease. J Parkinsons Dis. 2019;9(4):825.","journal-title":"J Parkinsons Dis"},{"issue":"3","key":"3839_CR35","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/psp4.12753","volume":"11","author":"K Lingineni","year":"2022","unstructured":"Lingineni K, Aggarwal V, Morales JF, Conrado DJ, Corey D, Vong C, et al. Development of a model-based clinical trial simulation platform to optimize the design of clinical trials for Duchenne muscular dystrophy. CPT Pharmacometrics Syst Pharmacol. 2022;11(3):318\u201332.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"3839_CR36","doi-asserted-by":"publisher","first-page":"103152","DOI":"10.1016\/j.jddst.2022.103152","volume":"69","author":"K Yuvaneshwari","year":"2022","unstructured":"Yuvaneshwari K, Kollipara S, Ahmed T, Chachad S. Applications of PBPK\/PBBM modeling in generic product development: an industry perspective. J Drug Deliv Sci Tec. 2022;69:103152.","journal-title":"J Drug Deliv Sci Tec."},{"key":"3839_CR37","unstructured":"European medicines agency, qualification of novel methodologies for medicine development. Available from: https:\/\/www.ema.europa.eu\/en\/qualification-novel-methodologies-medicine-development. Accessed 18 Feb 2025."}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03839-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-025-03839-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03839-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T15:14:44Z","timestamp":1749654884000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-025-03839-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["3839"],"URL":"https:\/\/doi.org\/10.1007\/s11095-025-03839-x","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"type":"print","value":"0724-8741"},{"type":"electronic","value":"1573-904X"}],"subject":[],"published":{"date-parts":[[2025,3,7]]},"assertion":[{"value":"18 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The opinions expressed in the manuscript are those of the authors and should not be interpreted as the position of their organizations\/employers. The contents of the manuscript are those of the authors and do not necessarily represent the official views of, nor an endorsement, by FDA\/HHS, or the U.S. Government.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}